Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced that Caidya, a leading global, mid-sized clinical research organization (CRO), has invested in additional solutions within the Medidata Experiences, including Clinical Trial Management System (CTMS) and Clinical Data Studio. With Medidata already supporting over 80% of its trials, this growing partnership positions Caidya to connect workflows, data, and teams across the trial lifecycle that enables more data-driven decision-making for a variety of therapeutic areas.
“As the clinical development landscape rapidly evolves, Caidya is looking to adopt more unified, intelligent platforms that empower sponsors to move faster and make smarter, more confident decisions,” said John Scott, chief information officer, Caidya. “In a competitive landscape increasingly dominated by technology-first narratives, our bet is different: combining cutting-edge technology with personalized implementation alongside Medidata. We view Medidata as a key partner, foundational to our ability to deliver white-glove service and data-driven outcomes across therapeutic areas.”
Medidata is reimagining clinical trial operations by integrating AI-powered insights into CTMS which will lead to timely and localized decisions, ultimately improving execution and patient outcomes. Additionally, Clinical Data Studio will allow sponsors to draw information from diverse sources and leverage AI to optimize data aggregation and management workflows, aiming to reduce review cycles by up to 80%.
“Caidya is setting a new standard for what it means to be a modern CRO,” said Janet Butler, executive vice president, head of global sales, Medidata. “Their willingness to invest in a broad set of solutions, including CTMS and Clinical Data Studio, speaks to a broader industry shift, one that places Caidya at the forefront of digital transformation in the CRO space, distinguished by speed, agility, and trust.”
Conducting studies in over 50 countries and regions, Caidya specializes in oncology and hematology, rare diseases, pediatrics, cell and gene therapy, cardiovascular, and dermatology. It has emerged as a frontrunner in the mid-sized CRO segment of the sector.
To view the original press release, please click here.
